Dataset Information


A confirmatory study on the efficacy of dehydrated human amnion/chorion membrane dHACM allograft in the management of diabetic foot ulcers: A prospective, multicentre, randomised, controlled study of 110 patients from 14 wound clinics.

ABSTRACT: A randomised, controlled multicentre clinical trial was conducted at 14 wound care centres in the United States to confirm the efficacy of dehydrated human amnion/chorion membrane allograft (dHACM) for the treatment of chronic lower extremity ulcers in persons with diabetes. Patients with a lower extremity ulcer of at least 4 weeks duration were entered into a 2-week study run-in phase and treated with alginate wound dressings and appropriate offloading. Those with less than or equal to 25% wound closure after run-in were randomly assigned to receive weekly dHACM application in addition to offloading or standard of care with alginate wound dressings, for 12?weeks. A total of 110 patients were included in the intent-to-treat (ITT) analysis, with n =?54 in the dHACM group and n =?56 in the no-dHACM group. Of the participants, 98 completed the study per protocol, with 47 receiving dHACM and 51 not receiving dHACM. The primary study outcome was percentage of study ulcers completely healed in 12?weeks, with both ITT and per-protocol participants receiving weekly dHACM significantly more likely to completely heal than those not receiving dHACM (ITT-70% versus 50%, P = 0.0338, per-protocol-81% versus 55%, P = 0.0093). A Kaplan-Meier analysis was performed to compare the time-to-healing performance with/without dHACM, showing a significantly improved time to healing with the use of allograft, log-rank P < 0.0187. Cox regression analysis showed that dHACM-treated subjects were more than twice as likely to heal completely within 12?weeks than no-dHACM subjects (HR: 2.15, 95% confidence interval 1.30-3.57, P = 0.003). At the final follow up at 16?weeks, 95% of dHACM-healed ulcers and 86% of healed ulcers in the no-dHACM group remained closed. These results confirm that dHACM is an efficacious treatment for lower extremity ulcers in a heterogeneous patient population.

SUBMITTER: Tettelbach W 

PROVIDER: S-EPMC7379535 | BioStudies | 2019-01-01

REPOSITORIES: biostudies

Similar Datasets

2019-01-01 | S-EPMC7380046 | BioStudies
2019-01-01 | S-EPMC6850648 | BioStudies
2017-01-01 | S-EPMC5950983 | BioStudies
2013-01-01 | S-EPMC3907779 | BioStudies
2020-01-01 | S-EPMC7093794 | BioStudies
1000-01-01 | S-EPMC3369130 | BioStudies
2018-01-01 | S-EPMC5819289 | BioStudies
2020-01-01 | S-EPMC6940587 | BioStudies
2019-01-01 | S-EPMC6754878 | BioStudies
2020-01-01 | S-EPMC7096556 | BioStudies